<p>MannKind 公司（NASDAQ:MNKD - 获取免费报告）在周二交易前股价跳空下跌。该股票此前收于 4.69 美元，但开盘价为 4.58 美元。MannKind 的股票最后交易价格为 4.77 美元，成交量为 104,293 股。</p>
<h2>分析师评级调整</h2>
<p>多家研究机构最近对 MNKD 进行了评估。加拿大皇家银行将 MannKind 的评级从 “行业表现” 上调至 “跑赢大盘”，并在 12 月 19 日的研究报告中将该公司的目标价从 7.00 美元上调至 10.00 美元。富国银行在 12 月 20 日的报告中开始覆盖 MannKind 的股票，给予 “增持” 评级，目标价为 9.00 美元。StockNews.com 在 3 月 19 日的研究报告中将 MannKind 的股票评级从 “持有” 上调至 “买入”。最后，Wedbush 在 2 月 27 日的研究报告中重申了 “跑赢大盘” 的评级，并将 MannKind 的目标价设定为 11.00 美元。八位投资分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “买入”，平均目标价为 9.21 美元。</p>
<p><strong>查看我们对 MannKind 的最新股票分析</strong></p>
<h2>MannKind 股票上涨 0.1%</h2>
<p>该公司的市值为 14.3 亿美元，市盈率为 67.07，贝塔值为 1.22。该股票的 50 日移动平均线为 5.35 美元，200 日移动平均线为 6.14 美元。</p>
<p>MannKind（NASDAQ:MNKD - 获取免费报告）最近于 2 月 26 日发布了季度财报。这家生物制药公司报告本季度每股收益为 0.03 美元，符合市场共识预期。该公司本季度的收入为 7678 万美元，而分析师预期为 7499 万美元。MannKind 的股本回报率为-17.74%，净利润率为 8.07%。分析师预计 MannKind 公司在当前财年将发布 0.1 美元的每股收益。</p>
<h2>机构投资者对 MannKind 的看法</h2>
<p>对冲基金和其他机构投资者最近调整了对该公司的持股。麦肯齐金融公司在第四季度将其在 MannKind 的持股增加了 146.6%。麦肯齐金融公司目前拥有 80218 股生物制药公司的股票，价值 516,000 美元，此前在上个季度购买了 47,690 股。GF 基金管理有限公司在第四季度购买了 MannKind 的新股份，价值约 37,000 美元。Focus Partners Advisor Solutions LLC 在第四季度购买了 MannKind 的新股份，价值约 111,000 美元。瑞银资产管理美洲有限公司的一个独立业务部门在第四季度将其在 MannKind 的持股增加了 7.1%。瑞银资产管理美洲有限公司的一个独立业务部门目前拥有 617,670 股生物制药公司的股票，价值 3,972,000 美元，此前在该期间购买了 41,142 股。最后，Waverly Advisors LLC 在第四季度购买了 MannKind 的新股份，价值 72,000 美元。目前 49.55% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>MannKind 公司简介</h2>
<p>（获取免费报告）</p>
<p>MannKind 公司是一家生物制药公司，专注于在美国开发和商业化用于内分泌和孤儿肺病的吸入治疗产品。它提供 Afrezza，这是一种用于改善糖尿病成人血糖控制的吸入胰岛素，以及 V-Go 可穿戴胰岛素输送设备，能够为成人提供持续的皮下胰岛素输注。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 MannKind</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>免关税股票：三只具有巨大上涨潜力的超值股票</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>高通股价下跌，但相对强弱指数显示其严重超卖</li>
<li>什么是国债？</li>
<li>特斯拉的第一大牛股下调目标价，但仍表示值得买入</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MannKind 吗？</h2>
<p>在考虑 MannKind 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 MannKind 并不在名单上。</p>
<p>虽然 MannKind 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

曼恩凯德生物医疗

<p>MannKind（纳斯达克代码：MNKD）股价在开盘前从 4.69 美元跳空下跌至 4.58 美元，最终收于 4.77 美元，成交量为 104,293 股。分析师们对该股票进行了升级，加拿大皇家银行将其评级提高至 “跑赢大盘”，并设定了 10.00 美元的目标价。平均评级为 “买入”，目标价为 9.21 美元。MannKind 报告了上一季度每股收益为 0.03 美元，收入为 7678 万美元。机构投资者持有该股票的 49.55%，公司专注于用于糖尿病和肺部疾病的吸入式治疗产品</p>

<p>MannKind Co. (NASDAQ:MNKD - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $4.69, but opened at $4.58. MannKind shares last traded at $4.77, with a volume of 104,293 shares traded.</p>
<div class="lb-trans"><p>MannKind 公司（NASDAQ:MNKD - 获取免费报告）在周二交易前股价跳空下跌。该股票此前收于 4.69 美元，但开盘价为 4.58 美元。MannKind 的股票最后交易价格为 4.77 美元，成交量为 104,293 股。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of research firms have recently weighed in on MNKD. Royal Bank of Canada raised MannKind from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and lifted their price objective for the company from $7.00 to $10.00 in a research report on Thursday, December 19th. Wells Fargo &amp; Company assumed coverage on shares of MannKind in a report on Friday, December 20th. They set an &#34;overweight&#34; rating and a $9.00 price target on the stock. StockNews.com upgraded shares of MannKind from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday, March 19th. Finally, Wedbush restated an &#34;outperform&#34; rating and set a $11.00 price objective on shares of MannKind in a research report on Thursday, February 27th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of &#34;Buy&#34; and an average price target of $9.21.</p>
<div class="lb-trans"><p>多家研究机构最近对 MNKD 进行了评估。加拿大皇家银行将 MannKind 的评级从 “行业表现” 上调至 “跑赢大盘”，并在 12 月 19 日的研究报告中将该公司的目标价从 7.00 美元上调至 10.00 美元。富国银行在 12 月 20 日的报告中开始覆盖 MannKind 的股票，给予 “增持” 评级，目标价为 9.00 美元。StockNews.com 在 3 月 19 日的研究报告中将 MannKind 的股票评级从 “持有” 上调至 “买入”。最后，Wedbush 在 2 月 27 日的研究报告中重申了 “跑赢大盘” 的评级，并将 MannKind 的目标价设定为 11.00 美元。八位投资分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “买入”，平均目标价为 9.21 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on MannKind</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MannKind 的最新股票分析</strong></p>
</div><h2>MannKind Stock Up 0.1 %</h2>
<div class="lb-trans"><h2>MannKind 股票上涨 0.1%</h2>
</div><p>The company has a market cap of $1.43 billion, a PE ratio of 67.07 and a beta of 1.22. The stock's 50 day moving average is $5.35 and its 200-day moving average is $6.14.</p>
<div class="lb-trans"><p>该公司的市值为 14.3 亿美元，市盈率为 67.07，贝塔值为 1.22。该股票的 50 日移动平均线为 5.35 美元，200 日移动平均线为 6.14 美元。</p>
</div><p>MannKind (NASDAQ:MNKD - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported $0.03 EPS for the quarter, hitting the consensus estimate of $0.03. The company had revenue of $76.78 million during the quarter, compared to analyst estimates of $74.99 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. On average, analysts anticipate that MannKind Co. will post 0.1 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MannKind（NASDAQ:MNKD - 获取免费报告）最近于 2 月 26 日发布了季度财报。这家生物制药公司报告本季度每股收益为 0.03 美元，符合市场共识预期。该公司本季度的收入为 7678 万美元，而分析师预期为 7499 万美元。MannKind 的股本回报率为-17.74%，净利润率为 8.07%。分析师预计 MannKind 公司在当前财年将发布 0.1 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On MannKind</h2>
<div class="lb-trans"><h2>机构投资者对 MannKind 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the business. Mackenzie Financial Corp grew its holdings in shares of MannKind by 146.6% in the fourth quarter. Mackenzie Financial Corp now owns 80,218 shares of the biopharmaceutical company's stock worth $516,000 after purchasing an additional 47,690 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of MannKind during the fourth quarter valued at approximately $37,000. Focus Partners Advisor Solutions LLC purchased a new stake in shares of MannKind in the fourth quarter valued at approximately $111,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in MannKind by 7.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 617,670 shares of the biopharmaceutical company's stock worth $3,972,000 after purchasing an additional 41,142 shares during the period. Finally, Waverly Advisors LLC bought a new stake in MannKind during the 4th quarter valued at $72,000. 49.55% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近调整了对该公司的持股。麦肯齐金融公司在第四季度将其在 MannKind 的持股增加了 146.6%。麦肯齐金融公司目前拥有 80218 股生物制药公司的股票，价值 516,000 美元，此前在上个季度购买了 47,690 股。GF 基金管理有限公司在第四季度购买了 MannKind 的新股份，价值约 37,000 美元。Focus Partners Advisor Solutions LLC 在第四季度购买了 MannKind 的新股份，价值约 111,000 美元。瑞银资产管理美洲有限公司的一个独立业务部门在第四季度将其在 MannKind 的持股增加了 7.1%。瑞银资产管理美洲有限公司的一个独立业务部门目前拥有 617,670 股生物制药公司的股票，价值 3,972,000 美元，此前在该期间购买了 41,142 股。最后，Waverly Advisors LLC 在第四季度购买了 MannKind 的新股份，价值 72,000 美元。目前 49.55% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>MannKind Company Profile</h2>
<div class="lb-trans"><h2>MannKind 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.</p>
<div class="lb-trans"><p>MannKind 公司是一家生物制药公司，专注于在美国开发和商业化用于内分泌和孤儿肺病的吸入治疗产品。它提供 Afrezza，这是一种用于改善糖尿病成人血糖控制的吸入胰岛素，以及 V-Go 可穿戴胰岛素输送设备，能够为成人提供持续的皮下胰岛素输注。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than MannKind</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Qualcomm Breaks Down But RSI Signals It’s Severely Oversold</li>
<li>What Are Treasury Bonds?</li>
<li>Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MannKind</li>
<li>什么是股息冠军？如何投资于冠军</li>
<li>免关税股票：三只具有巨大上涨潜力的超值股票</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>高通股价下跌，但相对强弱指数显示其严重超卖</li>
<li>什么是国债？</li>
<li>特斯拉的第一大牛股下调目标价，但仍表示值得买入</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MannKind Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MannKind 吗？</h2>
</div><p>Before you consider MannKind, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MannKind 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 MannKind 并不在名单上。</p>
</div><p>While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MannKind 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

曼恩凯德生物医疗（NASDAQ:MNKD）股价跳空下跌 - 你应该卖出吗？